Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vera Therapeutics, Inc. (Nasdaq: VERA) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a late clinical-stage biotechnology company focused on serious immunological diseases, Vera Therapeutics uses SEC filings to report clinical milestones, financing transactions, governance changes, and other material events that can be important for investors analyzing VERA stock.
Current reports on Form 8-K feature prominently in Vera Therapeutics’ filing history. For example, the company has filed 8-Ks describing entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, the pricing of underwritten public offerings of Class A common stock, and the termination of a prior sales agreement. Other 8-Ks report clinical and regulatory updates, such as ORIGIN Phase 3 trial data for atacicept in immunoglobulin A nephropathy (IgAN), including reductions in proteinuria and safety outcomes, as well as the submission of a Biologics License Application and subsequent communications around FDA review.
Filings also cover corporate governance and compensation. Vera Therapeutics has reported the appointment of new directors, including committee assignments and equity compensation under its non-employee director compensation policy, and changes in executive roles such as the departure of its Chief Legal Officer. Additional disclosures describe inducement equity awards granted under the company’s 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Alongside 8-Ks, investors can access registration statements and prospectus supplements referenced in the filings, which relate to public offerings and shelf registration on Form S-3. These documents outline the terms under which Vera Therapeutics may issue Class A common stock to fund its development programs, including atacicept, VT-109, and MAU868.
On Stock Titan, Vera Therapeutics’ SEC filings are updated in near real time from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as clinical trial disclosures, financing capacity, director and officer changes, and at-the-market sales arrangements. Users can quickly scan which filings relate to clinical data, capital raising, or governance, and then drill down into the full text when more detail is needed.
For those tracking insider and equity-related activity, the filings page complements Forms 4 and other ownership reports by surfacing information on option grants, RSUs, and inducement awards described in 8-Ks. Together, these materials provide a detailed view of how Vera Therapeutics structures incentives and finances its late-stage development efforts in immunology and nephrology.
Vera Therapeutics, Inc. was reported as having 1,229,525 shares of Class A Common Stock beneficially owned by Point72-affiliated filers, representing 1.7% of the class as of March 31, 2026. The reported holdings include 17,800 shares issuable upon exercise of call options held by the managed fund. The filing is a joint Schedule 13G by Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen and states that the reporting persons have shared voting and dispositive power over the 1,229,525 shares.
Vera Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Vera Therapeutics common stock, representing 0% of the class, following an internal realignment.
The filing states that on January 12, 2026 Vanguard reorganized and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim on 03/27/2026.
Vera Therapeutics Chief Legal Officer Jane Wright-Mitchell received new equity awards. She was granted a stock option for 56,850 shares of Class A Common Stock at an exercise price of $40.73 per share, expiring on March 22, 2036.
She also received 42,403 restricted stock units under the 2024 Inducement Plan, representing 42,403 shares of Class A Common Stock. According to the vesting terms, one-fourth of the RSUs vest on each of May 20, 2027, 2028, 2029 and 2030, while the option vests 12/48ths on March 23, 2027 and 1/48th monthly thereafter, in each case contingent on continued service.
Vera Therapeutics, Inc. filed an initial insider ownership report for Chief Legal Officer Jane Wright-Mitchell. This Form 3 establishes her status as an officer subject to insider reporting rules. The structured data provided shows no insider share transactions or derivative holdings reported in this filing.
Vera Therapeutics, Inc. senior vice president of finance and chief accounting officer Joseph R. Young exercised stock options to acquire 10,000 shares of Class A common stock at an exercise price of $3.9396 per share on March 13, 2026.
Following the transactions, he directly owns 75,754 shares of Class A common stock and holds 38,589 stock options. The filing notes that 1,032 of his shares were acquired through the company’s 2021 Employee Stock Purchase Plan, and the option grant vests over time, with a portion vesting monthly.
Vera Therapeutics reports a Schedule 13G filing showing Deep Track-affiliated holders beneficially own 3,921,362 shares of Class A common stock. That holding represents 5.50% of the class based on 71,355,667 shares outstanding as of February 23, 2026.
The filing lists Deep Track Capital, LP and Deep Track Biotechnology Master Fund, Ltd., with shared voting and dispositive power over the 3,921,362 shares, and identifies David Kroin as a control person for the Deep Track entities.
Vera Therapeutics reported that its board appointed Christopher Hite as a Class III director effective March 5, 2026, with his initial term running until the 2027 annual stockholders’ meeting. His compensation follows the company’s non-employee director policy.
On joining the board, Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share. The option vests monthly over three years, subject to his continued service. He will also receive an annual cash retainer of $45,000, pro-rated for 2026.
Beginning with the 2027 annual meeting, Hite will be eligible each year for an option to buy up to the lesser of 18,000 shares or the number of shares with a grant date fair value not above $400,000, vesting by the next annual meeting or one year from grant. He will sign the company’s standard indemnification agreement, and the company notes there were no special arrangements or related-person transactions tied to his selection.
Vera Therapeutics director receives stock option grant
Vera Therapeutics director Christopher Hite was granted an option to buy 24,937 shares of the company’s stock at an exercise price of $0.00 per share. The option vests monthly over three years, as long as he continues serving the company.
Vera Therapeutics, Inc. director Christopher Hite filed an initial ownership report on Form 3. The data provided lists him as a director of the company and shows no reportable stock transactions or holdings in the transaction section of the filing.
Sofinnova Venture Partners X and related entities now report owning less than 5% of Vera Therapeutics’ Class A common stock. They beneficially own 2,793,987 shares, representing 3.9% of the company, based on 71,355,667 shares outstanding as of February 23, 2026.
The group’s ownership fell below the 5% threshold as of September 30, 2025, primarily because Vera Therapeutics sold additional shares over time. Venture investor Sofinnova characterizes its position as held for investment purposes and may buy more, sell, or distribute shares depending on market conditions and company developments.